ALX Oncology Holdings Dirección
Dirección controles de criterios 2/4
El CEO de ALX Oncology Holdings' es Jason Lettmann , nombrado en Sep 2023, tiene una permanencia de menos de un año. compensación anual total es $5.32M, compuesta por 4.1% salario y 95.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.22% de las acciones de la empresa, por valor de $1.71M. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 3.8 años, respectivamente.
Información clave
Jason Lettmann
Chief Executive Officer (CEO)
US$5.3m
Compensación total
| Porcentaje del salario del CEO | 4.1% |
| Permanencia del CEO | less than a year |
| Participación del CEO | 0.2% |
| Permanencia media de la dirección | 2.8yrs |
| Promedio de permanencia en la Junta Directiva | 3.8yrs |
Actualizaciones recientes de la dirección
Recent updates
ALX Oncology: Trying To Justify The Hype
Apr 18Is ALX Oncology Holdings (NASDAQ:ALXO) Using Debt In A Risky Way?
Mar 12
ALX Oncology GAAP EPS of -$0.81 misses by $0.18
Aug 08ALX Oncology stock rises on FDA fast track status for evorpacept to treat head/neck cancer
Aug 01ALX Oncology stock rises 14% on evorpacept's FDA orphan drug status for blood cancer
Jun 29ALX Oncology Is Turning Into An Also-Ran In Anti-CD47
Feb 15ALX Oncology Stock: Attractive After Recent Data And Slump In Price
Nov 30ALX Oncology Is The Next CD47 Biotech To Watch After Recent Acquisitions In This Space
Sep 08Here's Why We're Not Too Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Situation
Jul 08Dosing underway in ALX Oncology's ALX148 combo study in head and neck cancer
May 10We're Not Very Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Rate
Mar 25Here's What ALX Oncology Holdings Inc.'s (NASDAQ:ALXO) Shareholder Ownership Structure Looks Like
Feb 01
ALX Oncology: All Their Eggs In The Proverbial Basket
Jan 07ALX Oncology (ALXO) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow
Dec 11ALX Oncology prices upsized stock offering at $76
Dec 10ALX Oncology announces proposed public offering
Dec 07ALX Oncology Holdings (ALXO) Presents New ALX148 Data from the Phase 1b Gastric/GEJ Expansion Cohort in ASPEN-01 - Slideshow
Nov 20ALX Oncology reports Q3 results
Nov 12Dosing underway for ALX Oncology's ALX148 in mid-stage blood cancer study
Oct 28Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$166m |
| Dec 31 2023 | US$5m | US$217k | -US$161m |
| Sep 30 2023 | n/a | n/a | -US$146m |
| Jun 30 2023 | n/a | n/a | -US$130m |
| Mar 31 2023 | n/a | n/a | -US$129m |
| Dec 31 2022 | US$116k | n/a | -US$123m |
| Sep 30 2022 | n/a | n/a | -US$121m |
| Jun 30 2022 | n/a | n/a | -US$110m |
| Mar 31 2022 | n/a | n/a | -US$94m |
| Dec 31 2021 | US$537k | n/a | -US$83m |
| Sep 30 2021 | n/a | n/a | -US$74m |
| Jun 30 2021 | n/a | n/a | -US$60m |
| Mar 31 2021 | n/a | n/a | -US$58m |
| Dec 31 2020 | US$352k | n/a | -US$51m |
Compensación vs. Mercado: La compensación total de Jason($USD5.32M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.40M).
Compensación vs. Ingresos: La compensación de Jason ha aumentado mientras la empresa no es rentable.
CEO
Jason Lettmann (46 yo)
less than a year
Permanencia
US$5,320,096
Compensación
Mr. Jason W. Lettmann had been an Independent Director of ALX Oncology Holdings Inc. since April 2020 until September 6, 2023 and previously served as a Director from March 2015 to May 2017 also serves as...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman | 9.2yrs | US$206.61k | 0.32% $ 2.6m | |
| CEO & Director | less than a year | US$5.32m | 0.21% $ 1.7m | |
| Founder | 9.1yrs | US$2.75m | 0.86% $ 7.0m | |
| Chief Financial Officer | 4.3yrs | US$1.30m | 0.075% $ 612.2k | |
| Chief Medical Officer & Director | 7.9yrs | US$1.37m | 0.50% $ 4.1m | |
| Vice President of Operations | no data | sin datos | sin datos | |
| Senior VP of Finance & Chief Accounting Officer | 3yrs | US$7.23m | 0.046% $ 374.1k | |
| Manager of Investor Relations & Corporate Communications | no data | sin datos | sin datos | |
| General Counsel | 2yrs | sin datos | sin datos | |
| Senior Vice President of Clinical Development | 2.5yrs | sin datos | sin datos | |
| Senior Vice President of Drug Safety & Pharmacovigilance | 1.9yrs | sin datos | sin datos | |
| Senior Vice President of Regulatory Affairs & Quality Assurance | less than a year | sin datos | sin datos |
2.8yrs
Permanencia media
55.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ALXO se considera experimentado (2.4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman | 9.2yrs | US$206.61k | 0.32% $ 2.6m | |
| CEO & Director | 4.1yrs | US$5.32m | 0.21% $ 1.7m | |
| Founder | 9.1yrs | US$2.75m | 0.86% $ 7.0m | |
| Chief Medical Officer & Director | 3.2yrs | US$1.37m | 0.50% $ 4.1m | |
| Independent Director | 4.3yrs | US$169.52k | 0% $ 0 | |
| Chair of the Scientific Advisory Board | 3.6yrs | sin datos | sin datos | |
| Independent Director | 1.5yrs | US$105.66k | 0% $ 0 | |
| Member of the Scientific Advisory Board | 3.6yrs | sin datos | sin datos | |
| Independent Director | 4.1yrs | US$181.02k | 0.0058% $ 46.8k | |
| Member of the Scientific Advisory Board | 3.6yrs | sin datos | sin datos |
3.8yrs
Permanencia media
55yo
Promedio de edad
Junta con experiencia: La junta directiva de ALXO se considera experimentada (3.5 años de antigüedad promedio).